The Medical University Of South Carolina

The Medical University of South Carolina (MUSC), a state-controlled comprehensive academic health sciences center and educational institution headquartered in Charleston, operates as a federal research and clinical services provider across biomedical research, clinical investigations, and healthcare delivery—primarily as a prime recipient on federal grants and a prime contractor on service delivery and research support agreements. MUSC competes predominantly in full-and-open procurements without set-aside designations, functioning as a state government entity ineligible for small business set-asides.

MUSC's capability portfolio centers on biomedical research, clinical trial conduct, healthcare delivery, educational support, and translational science. Representative work spans substance use disorder research (heroin-seeking behavior mechanisms, cannabis cessation, alcohol-use disorder treatments), oncology (pancreatic cancer therapeutics, renal cell carcinoma immunotherapy, cisplatin-induced hearing loss), neuroscience (Alzheimer's disease, spinal cord injury pain management, Parkinson's disease motor speech interventions), cardiovascular disease, maternal and child health, and infectious disease. Recent examples include a $3.55 million firm fixed-price contract with Veterans Integrated Service Network 7 for offsite dental support services (awarded August 2026, completing July 2031), a $1.1 million research assistance delivery order with VISN 7 (awarded January 2026), and a $5.73 million grant from the National Institute of Nursing Research for a COPD respiratory muscle strength training intervention delivered to rural populations (awarded March 2026). MUSC also delivers educational tuition and clinical support services to military personnel through Basic Ordering Agreements with the Department of the Navy.

Customer concentration is substantial but distributed across multiple federal agencies. The top five customers by combined potential value account for 86% of MUSC's recent award base: the Department of Veterans Affairs Veterans Integrated Service Network 7 (212 awards, $77.8 million combined potential value), the National Institute on Alcohol Abuse and Alcoholism (99 awards, $57 million), the Department of the Navy Bureau of Medicine and Surgery (279 awards, $25.5 million), the National Institute of Child Health and Human Development (35 awards, $16.7 million), and the National Heart Lung and Blood Institute (115 awards, $5 million). By award count, MUSC serves 108 distinct federal agencies across the HHS NIH component, VA, DoD, and independent agencies including FEMA and NSF. The top award types by volume reflect the institution's research and education mission: colleges/universities/professional schools (336 awards), testing laboratories and services (137 awards), general medical and surgical hospitals (62 awards), and reference laboratory testing (153 awards under PSC classification).

MUSC holds positions on multiple parent vehicles anchoring its task-order work. The top five vehicles by task-order volume are Indefinite Delivery Contract N0060085G1790 (207 task orders, $14.8 million combined potential value), Indefinite Delivery Contract N0014098G2526 (75 task orders, $10.6 million), VA Indefinite Delivery Contract VA24017D0028 (72 task orders, $16.6 million), Indefinite Delivery Contract 36C24E22D0008 (53 task orders, $16.4 million), and a Navy BOA established March 1, 2025, with a $0 ceiling value authorizing tuition and educational support services for military personnel with task orders issued through February 28, 2035. The Navy BOA alone has generated over $12 million in task orders since June 2022, reflecting sustained demand for MUSC's educational and research support services.

MUSC's activity trajectory shows volatility. Award counts per year rose from 152 in 2023 to a peak of 238 in 2024, declining to 181 in 2025 and 133 in 2026, with only 7 awards recorded in 2027 (through the source snapshot date). Over the next 24 months, 211 awards (combined potential value $4.1 million) reach ultimate completion, representing moderate recompete exposure concentrated in biomedical research and healthcare delivery categories with annual cyclicity driven by NIH funding calendars.

MUSC operates as an 85% prime and 15% subcontractor across its federal footprint. Across SCI-reportable prime service contracts, subcontractor hours represent an average of 7% of total contractor hours delivered, with 6 named subcontractors reported. SCI-recorded invoicing totaled $8.3 million across FY2022–FY2025 (FY2024 peak at $3.5 million), spanning 4.5 to 24.4 FTEs annually. Government-paid hourly rates on SCI-reported work range from a 10th-percentile floor of $2.50/hr to a 90th-percentile ceiling of $159.74/hr, with a median rate of $47.77/hr, reflecting MUSC's mix of research technician, nursing, clinical, and administrative labor. SCI dollars represent a subset of MUSC's federal services activity and a fraction of total enterprise revenue; the institution's federal footprint extends far beyond SCI through grant awards, educational contracts, and clinical delivery.

MUSC functions as a prime recipient across a distributed federal grant portfolio spanning substance abuse and mental health (NIDA, NIAAA, SAMHSA), oncology and cancer biology (NCI), cardiovascular and lung disease (NHLBI, NIDCD), neurological disorders (NINDS, NIA), maternal and child health (NICHD), and supporting programs (NSF, FEMA, Defense Health Agency). Representative recent grants include $602 thousand for varenicline cannabis-use-disorder treatment trials (NIDA, awarded September 2026), $5.73 million for COPD rehabilitation services in rural communities (NINRS, awarded March 2026), $1.98 million for MASLD advanced-fibrosis detection in primary care (NIDDK, awarded September 2025), and $1.28 million for the NEURO-PRECISE center's Community Engagement and Outreach Core (NICHD, awarded September 2025). In its subcontractor role on grants, MUSC performs data coordination, biostatistics, specialized lab services (mass spectrometry imaging, single-cell genomics), and clinical research support for academic medical centers and research institutions serving as prime recipients.

The source carries no information regarding named parent corporations or subsidiaries beyond MUSC's status as a child entity of the State of South Carolina. MUSC operates under state educational governance and state appropriation structures characteristic of public university medical centers.